rhTNK-tPA
Sponsors
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd., General Hospital of Shenyang Military Region, Xinqiao Hospital of Chongqing, Beijing Tiantan Hospital, Xuanwu Hospital, Beijing
Conditions
Acute Ischemic StrokeAcute ST Elevation Myocardial InfarctionMinor Ischemic StrokeStroke, AcuteStroke, Ischemic
Phase 2
Phase 3
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
CompletedNCT04797013
Start: 2021-06-12End: 2022-07-15Updated: 2023-01-17
Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ
RecruitingNCT06414499
Start: 2025-07-09End: 2026-10-31Target: 1386Updated: 2025-07-24
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
RecruitingNCT07201688
Start: 2025-11-30End: 2027-09-30Target: 890Updated: 2025-12-16
Phase 4
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
CompletedNCT02835534
Start: 2016-05-31End: 2020-01-31Updated: 2022-05-25
Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
CompletedNCT05752916
Start: 2023-06-02End: 2025-10-28Updated: 2025-12-02